Werewolf TherapeuticsHOWL
HOWL
About: Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
Employees: 46
0
Funds holding %
of 7,407 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
107% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 14
38% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 8
4% more funds holding
Funds holding: 69 [Q3] → 72 (+3) [Q4]
8% more call options, than puts
Call options by funds: $43K | Put options by funds: $40K
0% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]
10.48% less ownership
Funds ownership: 73.7% [Q3] → 63.22% (-10.48%) [Q4]
39% less capital invested
Capital invested by funds: $68.3M [Q3] → $41.7M (-$26.6M) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$8
771%
upside
Avg. target
$11.50
1,151%
upside
High target
$15
1,532%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Wedbush Robert Driscoll 4% 1-year accuracy 2 / 47 met price target | 771%upside $8 | Outperform Reiterated | 12 Mar 2025 |
HC Wainwright & Co. Andres Maldonado 16% 1-year accuracy 8 / 51 met price target | 1,532%upside $15 | Buy Reiterated | 12 Mar 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
2 days ago
Werewolf Therapeutics Appoints Steven Bloom as Chief Business Officer
WATERTOWN, Mass., April 17, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced the appointment of Steven Bloom as Chief Business Officer. Mr. Bloom brings more than 35 years of experience in the life sciences industry leading teams in corporate development, commercial planning, corporate affairs, and strategic consulting.
Neutral
GlobeNewsWire
2 weeks ago
Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference
WATERTOWN, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced that Daniel J.
Neutral
GlobeNewsWire
1 month ago
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
– Full enrollment in cutaneous melanoma dose-expansion arms of Phase 1/1b clinical trial evaluating WTX-124 as monotherapy and in combination with pembrolizumab expected by the end of the first half and the second half of 2025, respectively –
Neutral
GlobeNewsWire
1 month ago
Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference
WATERTOWN, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced that Daniel J.
Neutral
GlobeNewsWire
1 month ago
Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors
WATERTOWN, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and immunological diseases, today announced the appointment of Anil Singhal, Ph.D., President and Chief Executive Officer of Trishula Therapeutics, as a member of its board of directors.
Neutral
GlobeNewsWire
3 months ago
Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook
– Data from expansion arms in Phase 1/1b clinical trial evaluating WTX-124 as monotherapy expected in first half of 2025 to guide regulatory engagement on potential registrational pathways –
Neutral
GlobeNewsWire
4 months ago
Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference
WATERTOWN, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, and Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will participate in a fireside chat at 12:55 pm ET on Thursday, December 5, 2024, at the 7th Annual Evercore ISI HealthCONx Healthcare Conference, taking place December 3-5 in Miami, Florida.
Neutral
GlobeNewsWire
5 months ago
Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting
- Interim phase 1 clinical trial update reveals the clinical potential of the tumor-activated IL-12 prodrug WTX-330, with favorable tolerability profile and encouraging efficacy signals -
Neutral
GlobeNewsWire
6 months ago
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting
WATERTOWN, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer, today announced that two posters will be presented at the upcoming Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting, taking place November 6-10, 2024, in Houston, Texas.
Negative
Zacks Investment Research
8 months ago
Werewolf Therapeutics, Inc. (HOWL) Reports Q2 Loss, Lags Revenue Estimates
Werewolf Therapeutics, Inc. (HOWL) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.14 per share a year ago.
Charts implemented using Lightweight Charts™